Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW211026 in Actinic Keratosis
NCT07513454Phase 2Not yet recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HW211026 in actinic keratosis (AK), sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HW211026
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT07513454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513454.